Home > Annual Financials > VENUS REMEDIES

VENUS REMEDIES Financial Statement Analysis
[BOM: 526953|NSE : VENUSREM]

The Revenues of VENUS REMEDIES have increased by 8.55% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 126.84 % YoY.
COMMUNITY POLL
for VENUS REMEDIES
Please provide your vote to see the results

VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]

ConsolidatedMar2026
Mar2025
Mar2024
Mar2023
Mar2022
Revenues ₹653 Cr₹601 Cr₹556 Cr₹600 Cr₹548 Cr
Expenses ₹584 Cr₹542 Cr₹495 Cr₹538 Cr₹494 Cr
Operating Profit (Excl OI) ₹69 Cr₹60 Cr₹60 Cr₹62 Cr₹54 Cr
Other Income ₹16 Cr₹12 Cr₹10 Cr₹8.31 Cr₹20 Cr
Interest ₹0.07 Cr₹0.09 Cr₹0.12 Cr₹0.48 Cr₹13 Cr
Depreciation ₹23 Cr₹26 Cr₹32 Cr₹34 Cr₹35 Cr
Profit Before Tax ₹72 Cr₹45 Cr₹38 Cr₹36 Cr₹49 Cr
Profit After Tax ₹45 Cr₹28 Cr₹27 Cr₹41 Cr₹62 Cr
Consolidated Net Profit ₹45 Cr₹28 Cr₹27 Cr₹41 Cr₹62 Cr
Earnings Per Share (Rs)₹76.90₹33.90₹21.31₹19.87₹30.47
PAT Margin (%)13.366.944.744.786.79
ROE(%)16.798.646.015.909.85
ROCE(%)21.8813.178.677.727.89
Total Debt/Equity(x)0.000.000.080.090.10

Key Financials

Market Cap : ₹ 2,099.2 Cr
Revenue (TTM) : ₹ 811.3 Cr
Net Profit(TTM) : ₹ 116.2 Cr
EPS (TTM) : ₹ 86.7
P/E (TTM) : 18.1

Industry Peers & Returns1W1M1Y
VENUS REMEDIES -0.2% -11.3% 204.1%
SUN PHARMACEUTICAL INDUSTRIES 0.8% 6.3% 18.2%
DIVIS LABORATORIES 8.6% 20.7% 18.5%
TORRENT PHARMACEUTICALS 1.7% 9.4% 38.5%
CIPLA 4.5% 1.2% -1.4%
DR REDDYS LABORATORIES -0.3% -14.8% -9.5%
MANKIND PHARMA -3.2% -0.7% -0.4%
LUPIN 0.2% 0.6% 24.5%
ZYDUS LIFESCIENCES 1.7% 2.4% 14.9%


VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

8.55 %

5 Yr CAGR

4.47 %

Years Revenues % Change
Mar2026 ₹653 Cr
8.55
Mar2025 ₹601 Cr
8.27
Mar2024 ₹556 Cr
-7.44
Mar2023 ₹600 Cr
9.50
Mar2022 ₹548 Cr -


VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

14.99 %

5 Yr CAGR

6.25 %

Years Operating Profit % Change
Mar2026 ₹69 Cr
14.99
Mar2025 ₹60 Cr
-0.71
Mar2024 ₹60 Cr
-3.36
Mar2023 ₹62 Cr
15.50
Mar2022 ₹54 Cr -

Operating Margins
Y-o-Y

5.95 %

5 Yr CAGR

1.71 %

Years Operating Margin% % Change
Mar2026 10.5%
5.95
Mar2025 9.91%
-8.33
Mar2024 10.81%
4.44
Mar2023 10.35%
5.50
Mar2022 9.81% -

VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

59.05 %

5 Yr CAGR

-7.45 %

Years Profit After Tax % Change
Mar2026 ₹45 Cr
59.05
Mar2025 ₹28 Cr
7.25
Mar2024 ₹27 Cr
-34.77
Mar2023 ₹41 Cr
-34.07
Mar2022 ₹62 Cr -

PAT Margins
Y-o-Y

92.51 %

5 Yr CAGR

18.44 %

Years PAT Margin(%) % Change
Mar2026 13.36 %
92.51
Mar2025 6.94 %
46.41
Mar2024 4.74 %
-0.84
Mar2023 4.78 %
-29.60
Mar2022 6.79 % -

VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

126.84 %

5 Yr CAGR

26.04 %

Years EPS % Change
Mar2026 ₹77
126.84
Mar2025 ₹34
59.08
Mar2024 ₹21
7.25
Mar2023 ₹20
-34.79
Mar2022 ₹30 -

VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

66.14 %

5 Yr CAGR

29.05 %

Years ROCE % Change
Mar2026 21.88%
66.14
Mar2025 13.17%
51.90
Mar2024 8.67%
12.31
Mar2023 7.72%
-2.15
Mar2022 7.89% -

VENUS REMEDIES Share Price vs Sensex

Current Share Price : ₹1,566.6
Current MarketCap: ₹ 2,099.2 Cr
Updated EOD on :Jul 31,2026

Share Price Returns(%) 1 Week 1 Month 1 Year
VENUS REMEDIES

-0.2%

-11.3%

204.1%

SENSEX

2.7%

1.5%

-5.6%

VENUS REMEDIES related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about VENUS REMEDIES Financials


How the annual revenues of VENUS REMEDIES have changed ?

The Revenues of VENUS REMEDIES have increased by 8.55% YoY .

How the Earnings per Share (EPS) of VENUS REMEDIES have changed?

The Earnings Per Share (EPS) of VENUS REMEDIES has increased by 126.84 % YoY .